1377 / 1674
Endpoint: All Second Non-Breast Cancers
Overall number of studies:
Total number of Patients:
All second cancers:
Treatment years:
Range of FU:
7
299,883
14,472
1954 to 2007
0 to 37 years
0.5
1
2
4
Latency ≥ 5 years
RT
44%
NON-RT
56%
RT decreased risk
RT
increased
risk
Relative Risk (95% CI) IV Random
Studies, number of pt.
ES RR (95 CI%); Weight %
1.30 (0.95-1.79)
12
1.40 (1.12-1.75)
17
1.50 (1.06-2.12)
11
1.35 (0.51-3.59)
2
2.01 (1.16-3.48)
5
1.22 (1.06-1.41) 100
1.00 (0.91-1.10)
26
1.10 (1.00-1.10)
27
Schaapveld 2008,
<50 y
Schaapveld 2008,
>50 y
Grantzau 2012
(46,176)
(43,390)
(14,678)
Andersson 1991
(2,692)
Rubino 2000
(4,416)
Rutqvist 2006,
Premeopausal
(679)
Rutqvist 2006,
Postmeopausal
(547)
TOTAL; I
2
= 66%
TOTAL; I
2
= 15%
1.11 (1.06-1.16)
76
1.13 (1.01-1.27)
22
1.12 (1.06-1.19) 100
1.70 (0.98-2.94)
2
Grantzau 2012
Berrington d Gonzalez, 2010 (192,057)
(26,598)
Zhang 2011
(NR)